Matthew E. Cockman

Matthew E. Cockman

Auto-generated profile, based on publicly available information

Matthew E. Cockman

The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 1999 in Nature
Verified
Journal Article
Closed access
PDF file
PMPatrick H. Maxwell
Patrick H. Maxwell
MWMichael S. Wiesener
Michael S. Wiesener
GCGin-Wen Chang
Gin-Wen Chang
SCSteven C. Clifford
Steven C. Clifford
EVEmma C. Vaux
Emma C. Vaux
PRPeter J. Ratcliffe
Peter J. Ratcliffe

1 August 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MCMatthew E. Cockman
Matthew E. Cockman
NMNorma Masson
Norma Masson
DMDavid R. Mole
David R. Mole
PJPanu Jaakkola
Panu Jaakkola
GCGin-Wen Chang
Gin-Wen Chang
PMPatrick H. Maxwell
Patrick H. Maxwell
The von Hippel-Lindau tumor suppressor protein (pVHL) has emerged as a key factor in cellular responses to oxygen availability, being required for the oxygen-dependent proteolysis of α subunits of hypoxia inducible factor-1 (HIF). Mutations in VHL cause a hereditary cancer syndrome associated with dysregulated angiogenesis, and up-regulation of hypoxia inducible genes. Here we investigate the mechanisms underlying these processes and show that extracts from VHL-deficient renal carcinoma cells have a defect in HIF-α ubiquitylation activity which is complemented by exogenous pVHL. This defect was specific for HIF-α among a range of substrates tested. Furthermore, HIF-α subunits were the only pVHL-associated proteasomal substrates identified by comparison of metabolically labeled anti-pVHL immunoprecipitates from proteosomally inhibited cells and normal cells. Analysis of pVHL/HIF-α interactions defined short sequences of conserved residues within the internal transactivation domains of HIF-α molecules sufficient for recognition by pVHL. In contrast, while full-length pVHL and the p19 variant interact with HIF-α, the association was abrogated by further N-terminal and C-terminal truncations. The interaction was also disrupted by tumor-associated mutations in the β-domain of pVHL and loss of interaction was associated with defective HIF-α ubiquitylation and regulation, defining a mechanism by which these mutations generate a constitutively hypoxic pattern of gene expression promoting angiogenesis. The findings indicate that pVHL regulates HIF-α proteolysis by acting as the recognition component of a ubiquitin ligase complex, and support a model in which its β domain interacts with short recognition sequences in HIF-α subunits.

1 May 2001 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SCSteven C. Clifford
Steven C. Clifford
MCMatthew E. Cockman
Matthew E. Cockman
ASAlan C. Smallwood
Alan C. Smallwood
DMDavid R. Mole
David R. Mole
EWEmma R. Woodward
Emma R. Woodward
EMEamonn Richard Maher
Eamonn Richard Maher
The von Hippel-Lindau tumour suppressor gene product (pVHL) associates with the elongin B and C and Cul2 proteins to form a ubiquitin-ligase complex (VCBC). To date, the only VCBC substrates identified are the hypoxia-inducible factor α subunits (HIF-1α and HIF-2α). However, pVHL is thought to have multiple functions and the significance of HIF-1α and HIF-2α regulation for tumour suppressor activity has not been defined. VHL disease is characterized by distinct clinical subtypes. Thus haemangioblastomas (HABs) and renal cell carcinoma (RCC) but not phaeochromocytoma (PHE) occur in type 1 VHL disease. Type 2 subtypes are characterized by PHE susceptibility but differ with respect to additional tumours (type 2A, PHE+HAB but not RCC; type 2B, PHE+ HAB+RCC; type 2C, PHE only). We investigated in detail the effect of 13 naturally occurring VHL mutations (11 missense), representing each phenotypic subclass, on HIF-α subunit regulation. Consistent effects on pVHL function were observed for all mutations within each subclass. Mutations associated with the PHE-only phenotype (type 2C) promoted HIF-α ubiquitylation in vitro and demonstrated wild-type binding patterns with pVHL interacting proteins, suggesting that loss of other pVHL functions are necessary for PHE susceptibility. Mutations causing HAB susceptibility (types 1, 2A and 2B) demonstrated variable effects on HIF-α subunit and elongin binding, but all resulted in defective HIF-α regulation and loss of p220 (fibronectin) binding. All RCC-associated mutations caused complete HIF-α dysregulation and loss of p220 (fibronectin) binding. Our findings are consistent with impaired ability to degrade HIF-α subunit being required for HAB development and RCC susceptibility.

3 October 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MCMatthew E. Cockman
Matthew E. Cockman
DLDavid E. Lancaster
David E. Lancaster
ISIneke P. Stolze
Ineke P. Stolze
KHKirsty S. Hewitson
Kirsty S. Hewitson
MMMichael A. McDonough
Michael A. McDonough
PRPeter J. Ratcliffe
Peter J. Ratcliffe
Studies on hypoxia-sensitive pathways have revealed a series of Fe(II)-dependent dioxygenases that regulate hypoxia-inducible factor (HIF) by prolyl and asparaginyl hydroxylation. The recognition of these unprecedented signaling processes has led to a search for other substrates of the HIF hydroxylases. Here we show that the human HIF asparaginyl hydroxylase, factor inhibiting HIF (FIH), also efficiently hydroxylates specific asparaginyl (Asn)-residues within proteins of the IκB family. After the identification of a series of ankyrin repeat domain (ARD)-containing proteins in a screen for proteins interacting with FIH, the ARDs of p105 ( NFKB1 ) and IκBα were shown to be efficiently hydroxylated by FIH at specific Asn residues in the hairpin loops linking particular ankyrin repeats. The target Asn residue is highly conserved as part of the ankyrin consensus, and peptides derived from a diverse range of ARD-containing proteins supported FIH enzyme activity. These findings demonstrate that this type of protein hydroxylation is not restricted to HIF and strongly suggest that FIH-dependent ARD hydroxylation is a common occurrence, potentially providing an oxygen-sensitive signal to a diverse range of processes.

14 November 2018 in EMBO Reports
Verified
Journal Article
Open access
PDF file
JSJames A Smythies
James A Smythies
MSMin Sun
Min Sun
NMNorma Masson
Norma Masson
RSRafik Salama
Rafik Salama
PSPeter D Simpson
Peter D Simpson
DMDavid R. Mole
David R. Mole
Hypoxia‐inducible factor (HIF) is the major transcriptional regulator of cellular responses to hypoxia. The two principal HIF‐α isoforms, HIF‐1α and HIF‐2α, are progressively stabilized in response to hypoxia and form heterodimers with HIF‐1β to activate a broad range of transcriptional responses. Here, we report on the pan‐genomic distribution of isoform‐specific HIF binding in response to hypoxia of varying severity and duration, and in response to genetic ablation of each HIF‐α isoform. Our findings reveal that, despite an identical consensus recognition sequence in DNA, each HIF heterodimer loads progressively at a distinct repertoire of cell‐type‐specific sites across the genome, with little evidence of redistribution under any of the conditions examined. Marked biases towards promoter‐proximal binding of HIF‐1 and promoter‐distant binding of HIF‐2 were observed under all conditions and were consistent in multiple cell type. The findings imply that each HIF isoform has an inherent property that determines its binding distribution across the genome, which might be exploited to therapeutically target the specific transcriptional output of each isoform independently.

1 August 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MCMathew L. Coleman
Mathew L. Coleman
MMMichael A. McDonough
Michael A. McDonough
KHKirsty S. Hewitson
Kirsty S. Hewitson
CCCharlotte Coles
Charlotte Coles
Jasmin MecinovićJasmin Mecinović
Jasmin Mecinović
CSChristopher J. Schofield
Christopher J. Schofield
The stability and activity of hypoxia-inducible factor (HIF) are regulated by the post-translational hydroxylation of specific prolyl and asparaginyl residues. We show that the HIF asparaginyl hydroxylase, factor inhibiting HIF (FIH), also catalyzes hydroxylation of highly conserved asparaginyl residues within ankyrin repeat (AR) domains (ARDs) of endogenous Notch receptors. AR hydroxylation decreases the extent of ARD binding to FIH while not affecting signaling through the canonical Notch pathway. ARD proteins were found to efficiently compete with HIF for FIH-dependent hydroxylation. Crystallographic analyses of the hydroxylated Notch ARD (2.35A) and of Notch peptides bound to FIH (2.4-2.6A) reveal the stereochemistry of hydroxylation on the AR and imply that significant conformational changes are required in the ARD fold in order to enable hydroxylation at the FIH active site. We propose that ARD proteins function as natural inhibitors of FIH and that the hydroxylation status of these proteins provides another oxygen-dependent interface that modulates HIF signaling.